Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 01:10 UTC |
Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENT
|
SaleCommon shares without par value | 885 | $115.58 | $102,288.30 |
DisclosureSEC source: 0001620564-26-000007 · form4-03042026_010342.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,377 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 00:55 UTC |
MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER
|
SaleCommon shares without par value | 585 | $115.58 | $67,614.30 |
DisclosureSEC source: 0001644207-26-000007 · form4-03042026_120315.xml · nonDerivative · entry 2 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,628 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:00 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 613 | $115.58 | $70,850.54 |
DisclosureSEC source: 0001783147-26-000007 · form4-03042026_010311.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,291 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:06 UTC |
Morrone Louis H.EXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 1,144 | $115.58 | $132,223.52 |
DisclosureSEC source: 0001867666-26-000007 · form4-03042026_010349.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,843 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:20 UTC |
Shroff EricSenior Vice President
|
SaleCommon shares without par value | 709 | $115.58 | $81,946.22 |
DisclosureSEC source: 0002058129-26-000007 · form4-03042026_010300.xml · nonDerivative · entry 2 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,164 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 00:39 UTC |
Cushman Elizabeth C.EVP, GC AND SECRETARY
|
SaleCommon shares without par value | 263 | $115.58 | $30,397.54 |
DisclosureSEC source: 0002075371-26-000007 · form4-03042026_120334.xml · nonDerivative · entry 2 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,573 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:44 UTC |
Earnhardt Lisa DEVP AND GROUP PRESIDENT
|
Tax withholdingCommon shares without par value | 8,577 | $116.26 | $997,162.02 |
DisclosureSEC source: 0001530893-26-000004 · form4-03042026_120314.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,407 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:48 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
Tax withholdingCommon shares without par value | 30,308 | $116.26 | $3,523,608.08 |
DisclosureSEC source: 0001612571-26-000006 · form4-03042026_120340.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,461 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:10 UTC |
Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENT
|
Tax withholdingCommon shares without par value | 6,615 | $116.26 | $769,059.90 |
DisclosureSEC source: 0001620564-26-000007 · form4-03042026_010342.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,262 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:55 UTC |
MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER
|
Tax withholdingCommon shares without par value | 1,142 | $116.26 | $132,768.92 |
DisclosureSEC source: 0001644207-26-000007 · form4-03042026_120315.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,213 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:15 UTC |
Scoggins Christopher JEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,997 | $116.26 | $580,951.22 |
DisclosureSEC source: 0001772286-26-000004 · form4-03042026_010323.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,126 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:00 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,630 | $116.26 | $538,283.80 |
DisclosureSEC source: 0001783147-26-000007 · form4-03042026_010311.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,904 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:34 UTC |
Boudreau Philip PEVP AND CFO
|
Tax withholdingCommon shares without par value | 7,441 | $116.26 | $865,090.66 |
DisclosureSEC source: 0001805099-26-000004 · form4-03042026_120355.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,172 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:06 UTC |
Morrone Louis H.EXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,040 | $116.26 | $469,690.40 |
DisclosureSEC source: 0001867666-26-000007 · form4-03042026_010349.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,987 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:20 UTC |
Shroff EricSenior Vice President
|
Tax withholdingCommon shares without par value | 1,384 | $116.26 | $160,903.84 |
DisclosureSEC source: 0002058129-26-000007 · form4-03042026_010300.xml · nonDerivative · entry 1 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,873 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:39 UTC |
Cushman Elizabeth C.EVP, GC AND SECRETARY
|
Tax withholdingCommon shares without par value | 1,421 | $116.26 | $165,205.46 |
DisclosureSEC source: 0002075371-26-000007 · form4-03042026_120334.xml · nonDerivative · entry 1 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,836 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:11 UTC |
Earnhardt Lisa DEVP AND GROUP PRESIDENT
|
GrantOption (right to buy) · Derivative | 111,533 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001530893-26-000002 · form4-02262026_110237.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,533 Underlying: Common Shares · 111,533 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,177 on February 24, 2027, 37,178 on February 24, 2028, and 37,178 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:11 UTC |
Earnhardt Lisa DEVP AND GROUP PRESIDENT
|
GrantCommon shares without par value | 27,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001530893-26-000002 · form4-02262026_110237.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,984 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:21 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
GrantOption (right to buy) · Derivative | 344,066 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001612571-26-000004 · form4-02262026_110221.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,066 Underlying: Common Shares · 344,066 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 114,688 on February 24, 2027, 114,689 on February 24, 2028, and 114,689 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:21 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
GrantCommon shares without par value | 83,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001612571-26-000004 · form4-02262026_110221.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,769 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:02 UTC |
Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENT
|
GrantOption (right to buy) · Derivative | 89,226 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001620564-26-000002 · form4-02272026_120229.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,226 Underlying: Common Shares · 89,226 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,742 on February 24, 2027, 29,742 on February 24, 2028, and 29,742 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:02 UTC |
Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENT
|
GrantCommon shares without par value | 21,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001620564-26-000002 · form4-02272026_120229.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,877 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:35 UTC |
MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER
|
GrantOption (right to buy) · Derivative | 22,151 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001644207-26-000002 · form4-02262026_110204.xml · derivative · entry 3 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,151 Underlying: Common Shares · 22,151 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,383 on February 24, 2027, 7,384 on February 24, 2028, and 7,384 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:35 UTC |
MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER
|
GrantCommon shares without par value | 5,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001644207-26-000002 · form4-02262026_110204.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,355 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:15 UTC |
Scoggins Christopher JEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 76,273 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001772286-26-000002 · form4-02272026_120215.xml · derivative · entry 2 Scoggins Christopher J · CIK 0001772286 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,273 Underlying: Common Shares · 76,273 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,424 on February 24, 2027, 25,424 on February 24, 2028, and 25,425 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:15 UTC |
Scoggins Christopher JEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 18,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001772286-26-000002 · form4-02272026_120215.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,123 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:43 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 57,512 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001783147-26-000002 · form4-02262026_110230.xml · derivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,512 Underlying: Common Shares · 57,512 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,170 on February 24, 2027, 19,171 on February 24, 2028, and 19,171 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:43 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 13,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001783147-26-000002 · form4-02262026_110230.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,534 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:46 UTC |
Boudreau Philip PEVP AND CFO
|
GrantOption (right to buy) · Derivative | 115,413 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001805099-26-000002 · form4-02262026_100226.xml · derivative · entry 3 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,413 Underlying: Common Shares · 115,413 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,471 on February 24, 2027, 38,471 on February 24, 2028, and 38,471 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:46 UTC |
Boudreau Philip PEVP AND CFO
|
GrantCommon shares without par value | 27,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001805099-26-000002 · form4-02262026_100226.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,613 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:52 UTC |
Morrone Louis H.EXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 63,561 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001867666-26-000002 · form4-02262026_110221.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,561 Underlying: Common Shares · 63,561 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,187 on February 24, 2027, 21,187 on February 24, 2028, and 21,187 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:52 UTC |
Morrone Louis H.EXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 15,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001867666-26-000002 · form4-02262026_110221.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,027 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:24 UTC |
Shroff EricSenior Vice President
|
GrantOption (right to buy) · Derivative | 44,821 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0002058129-26-000002 · form4-02272026_120249.xml · derivative · entry 2 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,821 Underlying: Common Shares · 44,821 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,940 on February 24, 2027, 14,940 on February 24, 2028, and 14,941 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:24 UTC |
Shroff EricSenior Vice President
|
GrantCommon shares without par value | 10,873 | $0.00 | $0.00 |
DisclosureSEC source: 0002058129-26-000002 · form4-02272026_120249.xml · nonDerivative · entry 1 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,257 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:01 UTC |
Cushman Elizabeth C.EVP, GC AND SECRETARY
|
GrantOption (right to buy) · Derivative | 61,964 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0002075371-26-000002 · form4-02262026_110256.xml · derivative · entry 2 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,964 Underlying: Common Shares · 61,964 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,654 on February 24, 2027, 20,655 on February 24, 2028, and 20,655 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:01 UTC |
Cushman Elizabeth C.EVP, GC AND SECRETARY
|
GrantCommon shares without par value | 15,031 | $0.00 | $0.00 |
DisclosureSEC source: 0002075371-26-000002 · form4-02262026_110256.xml · nonDerivative · entry 1 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,257 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 13:04 UTC |
STARKS DANIEL JDirector
|
PurchaseCommon shares without par value | 5,033 | $108.33 | $545,238.98 |
DisclosureSEC source: 0000902132-26-000003 · form4-02062026_010212.xml · nonDerivative · entry 2 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,738,817 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.7700 to $108.7150, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 13:04 UTC |
STARKS DANIEL JDirector
|
PurchaseCommon shares without par value | 4,967 | $109.14 | $542,092.42 |
DisclosureSEC source: 0000902132-26-000003 · form4-02062026_010212.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,733,784 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.8150 to $109.5204, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 13:02 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
PurchaseCommon shares without par value | 18,800 | $107.13 | $2,013,966.92 |
DisclosureSEC source: 0001612571-26-000002 · form4-01262026_010121.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ford Family Trust Disclosed balance after: 216,203 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.735 to $107.485, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:46 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 313 | $125.29 | $39,215.77 |
DisclosureSEC source: 0001385262-26-000002 · form4-01052026_110142.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,034 Underlying: Common Shares · 313 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:00 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 62 | $125.29 | $7,767.98 |
DisclosureSEC source: 0001448074-26-000004 · form4-01052026_110149.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,409 Underlying: Common Shares · 62 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:26 UTC |
Roman Michael FDirector
|
GrantStock Equivalent Units · Derivative | 301 | $125.29 | $37,712.29 |
DisclosureSEC source: 0001577544-26-000002 · form4-01052026_110105.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,882 Underlying: Common Shares · 301 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:15 UTC |
Gonzalez Patricia PaolaDirector
|
GrantStock Equivalent Units · Derivative | 263 | $125.29 | $32,951.27 |
DisclosureSEC source: 0001879701-26-000002 · form4-01052026_110137.xml · derivative · entry 1 Gonzalez Patricia Paola · CIK 0001879701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,208 Underlying: Common Shares · 263 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 22:04 UTC |
Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENT
|
GiftCommon shares without par value | 1,536 | $123.28 | $189,358.08 |
DisclosureSEC source: 0001620564-25-000009 · form4-12122025_101232.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,233 Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 21:17 UTC |
Shroff EricSenior Vice President
|
SaleCommon shares without par value | 1,586 | $128.02 | $203,042.57 |
DisclosureSEC source: 0002058129-25-000009 · form4-11252025_091124.xml · nonDerivative · entry 1 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,384 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.02 to $128.06, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 21:02 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 293 | $133.94 | $39,244.42 |
DisclosureSEC source: 0001385262-25-000009 · form4-10022025_091040.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,663 Underlying: Common Shares · 293 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:50 UTC |
Roman Michael FDirector
|
GrantStock Equivalent Units · Derivative | 281 | $133.94 | $37,637.14 |
DisclosureSEC source: 0001577544-25-000015 · form4-10022025_081034.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,556 Underlying: Common Shares · 281 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:34 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 58 | $133.94 | $7,768.52 |
DisclosureSEC source: 0001448074-25-000011 · form4-10022025_081051.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,300 Underlying: Common Shares · 58 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:42 UTC |
Gonzalez Patricia PaolaDirector
|
GrantStock Equivalent Units · Derivative | 246 | $133.94 | $32,949.24 |
DisclosureSEC source: 0001879701-25-000007 · form4-10022025_081013.xml · derivative · entry 1 Gonzalez Patricia Paola · CIK 0001879701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,922 Underlying: Common Shares · 246 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:31 UTC |
Boudreau Philip PEVP AND CFO
|
Tax withholdingCommon shares without par value | 387 | $132.66 | $51,339.42 |
DisclosureSEC source: 0001415889-25-023586 · form4-09032025_090923.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,616 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.